Two kinds of skin reaction in the documents
The Trulicity® documents separate allergic reactions that affect the whole body from reactions where the injection was given. [1][3] The US label lists hypersensitivity among its warnings, describes systemic reactions such as severe hives, widespread rash and swelling of the face or lips in 0.5% of adults in trials, and adds postmarketing reports of anaphylaxis and angioedema. [1] The EU summary classes hypersensitivity as uncommon and anaphylactic reaction and angioedema as rare, both taken from post-marketing reports. [3] Canada lists rash, itching and contact dermatitis among less common trial events. [4]
| Reaction | Rate or class | Comparison | Source |
|---|---|---|---|
| Systemic hypersensitivity (hives, widespread rash, facial or lip swelling), adults | 0.5% | — | US label 6.1 [1] |
| Injection-site reactions (rash, redness), adults | 0.5% | Placebo 0.0% | US label 6.1 [1] |
| Injection-site reactions, ages 10–17 | 3.9% (0.75 mg), 3.8% (1.5 mg) | Placebo 2.0% | US label 6.1 [1] |
| Hypersensitivity | Uncommon (≥1/1,000 to <1/100) | — | EU Table 1 [3] |
| Anaphylactic reaction; angioedema | Rare (≥1/10,000 to <1/1,000) | Post-marketing | EU Table 1 [3] |
| Rash, pruritus, contact dermatitis | Less common, no rate | — | Canada 8.3 [4] |
What studies and case reports add
A cohort study in three large US insurance databases followed 696,089 new users of GLP-1 medicines with type 2 diabetes. Anaphylaxis occurred in 3.9 per 10,000 person-years on dulaglutide, similar to 3.6 on semaglutide and 5.1 on liraglutide, and the authors concluded that anaphylaxis is rare across the class. [6]
A 2026 meta-analysis of randomised trials found that GLP-1 medicines raise the risk of injection-site reactions compared with other treatments, while body-wide skin events were infrequent and not significantly increased. [5] In US adverse event reports, dulaglutide showed a signal for bleeding at the injection site. [5] Another FAERS analysis found the lowest proportion of skin-related reports with dulaglutide among four GLP-1 medicines. [9]
Individual cases show what a drug rash can look like. One report described a man who developed a rash on the abdomen after his dulaglutide dose was raised; it cleared within days of stopping. [7] Another described a measles-like (morbilliform) eruption, which the authors called very rare. [8] Single cases cannot give a frequency, but they show why a new rash after a dose change is worth reporting.
Local reaction or allergy?
- Local: redness, a small rash, itching or a bruise limited to where you injected. The EU summary says injection-site reactions that may be immune-related were usually mild. [3] The Canadian monograph notes they were more frequent in the small group who developed antibodies to dulaglutide. [4]
- Allergic, body-wide: hives or rash away from the injection site, widespread itching, or swelling of the face, lips, tongue or throat. [2][3]
- Severe allergy (anaphylaxis): symptoms usually develop within seconds or minutes and can include trouble breathing, wheezing, swelling, dizziness, a racing heart, nausea or vomiting and collapse. [12]
- History matters: the label advises caution if you have had angioedema or anaphylaxis with another GLP-1 medicine, because it is not known whether that predicts a reaction to Trulicity®. [1]
Rashes that are not from Trulicity®
MedlinePlus explains that many rashes are dermatitis, an inflammation of the skin, often caused by contact with soaps, cosmetics, detergents, latex, clothing dyes or plants. [11] Eczema, psoriasis, seborrhoeic dermatitis, shingles, insect bites, infections and other medicines are common causes, and hives can also follow infections or stress. [10][11]
Because Trulicity® is often added to several other diabetes, blood pressure and cholesterol medicines, a new rash may come from something else started around the same time. MedlinePlus asks you to contact your provider about a rash when taking a new medicine and not to stop any medicine without talking to them. [11]
What the guidance describes
For a serious allergic reaction, the Medication Guide asks you to stop Trulicity® and get medical help right away. [2] The label adds that anyone who has had a serious allergic reaction to dulaglutide should not use it again. [1]
For mild rashes, MedlinePlus describes gentle skin care: avoiding scrubbing, using mild cleansers and lukewarm water, patting dry, stopping recently added cosmetics and leaving the area open to the air. It mentions non-prescription hydrocortisone cream and oral antihistamines for itch; ask a pharmacist before using them. [11] Rotating injection sites each week is part of the Trulicity® instructions. [2]
Trulicity® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| A swollen face, lips, tongue or throat, difficulty breathing or swallowing, collapse or a very rapid heartbeat | Stop Trulicity® and call emergency services (911 / 112) | Emergency | Medication Guide [2]; MedlinePlus [12] |
| Severe rash or itching, or hives with rapid swelling | Stop Trulicity® and get medical help right away | Emergency | Medication Guide [2]; EU leaflet [3] |
| Rash with fever, joint pain or a sore throat, or red streaks and tenderness suggesting infection | Your provider | Today | MedlinePlus [11] |
| New rash after a dose increase, or a local reaction that keeps returning at injection sites | Your prescriber | At your next appointment | US label [1]; case report [7] |
| Mild rash that does not improve with home care or gets worse | Your provider | At your next appointment | MedlinePlus [11] |
